Stockscreener 앱 받기
0.70
8.36%
0.054
시간 외 거래:
.70
전일 마감가:
$0.646
열려 있는:
$0.72
하루 거래량:
220.70K
Relative Volume:
0.88
시가총액:
$72.79M
수익:
$1.29M
순이익/손실:
$-29.87M
주가수익비율:
-1.9444
EPS:
-0.36
순현금흐름:
$-14.70M
1주 성능:
+5.90%
1개월 성능:
-2.11%
6개월 성능:
+9.03%
1년 성능:
+8.33%
1일 변동 폭
$0.66
$0.729
1주일 범위
$0.646
$0.729
52주 변동 폭
$0.3951
$0.94
VolitionRX Ltd Stock (VNRX) Company Profile
명칭
VolitionRX Ltd
전화
646 650 1351
주소
No. 24-05 Shaw Centre, 1 Scotts Road, Singapore, TX
VNRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VNRX
VolitionRX Ltd
|
0.70 | 68.73M | 1.29M | -29.87M | -14.70M | -0.36 |
|
TMO
Thermo Fisher Scientific Inc
|
416.31 | 158.50B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
193.30 | 143.82B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
520.57 | 43.48B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
113.43 | 34.46B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
158.64 | 28.03B | 15.50B | 1.33B | 2.16B | 7.34 |
VolitionRX Ltd Stock (VNRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-08 | 개시 | H.C. Wainwright | Buy |
| 2023-02-01 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2022-02-17 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-03-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-05-16 | 개시 | Maxim Group | Buy |
| 2018-05-14 | 재확인 | The Benchmark Company | Buy |
| 2016-09-07 | 재확인 | Rodman & Renshaw | Buy |
| 2016-02-01 | 개시 | Rodman & Renshaw | Buy |
모두보기
VolitionRX Ltd 주식(VNRX)의 최신 뉴스
Nu.Q® Discover Expands Global Adoption and Epigenetic Innovation - MarketScreener
How VolitionRx Limited stock performs during market volatilitySolid Return Trade Selections - Newser
Why VolitionRx Limited stock attracts strong analyst attentionDefensive Stock Picks with Upside - Newser
VolitionRx Limited Announces Lateral Flow Test for Point-of-Care Quantification of Nucleosomes - MarketScreener
Breakthrough: New 5-Minute Blood Test Could Transform Emergency Care and Sepsis Detection - Stock Titan
VNRX INVESTOR NOTICE: Kaskela Law LLC Announces Investigation of VolitionRx Ltd. (NYSE: VNRX) and Encourages Long-Term Investors to Contact the Firm - ACCESS Newswire
VolitionRx CEO Cameron Reynolds acquires $7,372 in common stock By Investing.com - Investing.com India
VolitionRx CEO Cameron Reynolds acquires $7,372 in common stock - Investing.com
Volition Announces MARS Consortium Clinical Study Suggests Nu.Q H3.1 Concentrations Are Closely Associated With Sepsis And Organ Failure - MarketScreener
VolitionRx (NYSE:VNRX) Rating Increased to Strong-Buy at Jones Trading - Defense World
VolitionRX (VNRX) Coverage Initiated with a 'Buy' Rating by Jones Trading | VNRX Stock News - GuruFocus
JonesTrading Initiates Coverage on VolitionRx Limited With Buy Rating, $3 Price Target - marketscreener.com
Jones Trading initiates VolitionRX with Buy, sets $3 target By Investing.com - Investing.com India
VolitionRx (VNRX) Receives Buy Rating with Promising Price Targe - GuruFocus
VolitionRx initiated with a Buy at JonesResearch - TipRanks
VolitionRx (VNRX) Receives Buy Rating with Promising Price Target | VNRX Stock News - GuruFocus
Director Makes Bold Move with Major VolitionRX Stock Purchase - TipRanks
Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties - Yahoo Finance
VolitionRx director Guy Innes buys $10,772 in common stock By Investing.com - Investing.com South Africa
VolitionRx director Guy Innes buys $10,772 in common stock - Investing.com
VNRX: Management's key financial goal for 2025 is to be cash neutral on a full year basis. - Research Tree
VNRX: Management’s key financial goal for 2025 is to be cash neutral on a full year basis. Four operational milestones have been achieved thus far in 2025. Primary operational goal is to enter into multiple licensing agreements for human diagnostic applicati - Yahoo Finance
VolitionRx Limited (AMEX:VNRX) Q1 2025 Earnings Call Transcript - Insider Monkey
VolitionRX Ltd. Earnings Call Reveals Promising Growth - TipRanks
VolitionRX shares hold as Benchmark maintains rating - Investing.com Australia
VNRX stock touches 52-week low at $0.42 amid market challenges - Investing.com Canada
VolitionRX shares hold as Benchmark maintains rating By Investing.com - Investing.com India
VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats - Yahoo Finance
VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats By Investing.com - Investing.com Canada
VolitionRX Ltd (VNRX) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Milestones - Yahoo Finance
VolitionRx Reports Strong Q1 2025 Performance - TipRanks
VolitionRX (VNRX) Sees Revenue Growth and Cost Reduction in Q1 2 - GuruFocus
Earnings call transcript: VolitionRx misses Q1 2025 earnings forecast By Investing.com - Investing.com Nigeria
Transcript : VolitionRx Limited, Q1 2025 Earnings Call, May 16, 2025 - marketscreener.com
Earnings call transcript: VolitionRx misses Q1 2025 earnings forecast - Investing.com
Volitionrx Ltd earnings missed by $0.02, revenue fell short of estimates - Investing.com UK
VolitionRX: Q1 Earnings Snapshot - CT Insider
VolitionRx Q1 2025 Earnings Call Transcript - MarketBeat
Volitionrx Ltd earnings missed by $0.03, revenue fell short of estimates - Investing.com South Africa
VolitionRx reports Q1 revenue $0.25M, consensus $1.08M - TipRanks
Volition (VNRX) Targets Diagnostic Market Expansion with Nu.Q Platform | VNRX Stock News - GuruFocus
VolitionRX Ltd Reports Q1 2025 Revenue of $0.25 Million, Missing - GuruFocus
VolitionRX Ltd (VNRX) Q1 2025 Earnings Report Preview: What To Look For - GuruFocus
VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update - Yahoo Finance
VolitionRx (VNRX) Expected to Announce Quarterly Earnings on Monday - Defense World
VolitionRx Limited Announces Closing of $16.5 Million Underwritten Public Offering of Common Stock - Barchart.com
VolitionRX Ltd (VNRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.00%
0.97%
자본화:
|
볼륨(24시간):